Heterologous Expression and Delivery of Biologically Active Exendin-4 by Lactobacillus paracasei L14

Zhu Zeng; Rui Yu; Fanglei Zuo; Bo Zhang; Deju Peng; Huiqin Ma; Shangwu Chen

doi:10.1371/journal.pone.0165130

Abstract

Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, is an excellent therapeutic peptide drug for type 2 diabetes due to longer lasting biological activity compared to GLP-1. This study explored the feasibility of using probiotic Lactobacillus paracasei as an oral vector for recombinant exendin-4 peptide delivery, an alternative to costly chemical synthesis and inconvenient administration by injection. L. paracasei transformed with a plasmid encoding the exendin-4 gene (L. paracasei L14/pMG76e-exendin-4) with a constitutive promotor was successfully constructed and showed efficient secretion of exendin-4. The secreted exendin-4 significantly enhanced insulin secretion of INS-1 β-cells, along with an increment in their proliferation and inhibition of their apoptosis, corresponding to the effect of GLP-1 on these cells. The transcription level of the pancreatic duodenal homeobox-1 gene (PDX-1), a key transcription factor for cellular insulin synthesis and secretion, was upregulated by the treatment with secreted exendin-4, paralleling the upregulation of insulin gene expression. Caco-2 cell monolayer permeability assay showed a 34-fold increase in the transport of exendin-4 delivered by L. paracasei vs. that of free exendin-4 (control), suggesting effective facilitation of exendin-4 transport across the intestinal barrier by this delivery system. This study demonstrates that the probiotic Lactobacillus can be engineered to secrete bioactive exendin-4 and facilitate its transport through the intestinal barrier, providing a novel strategy for oral exendin-4 delivery using this lactic acid bacterium.

Citation: Zeng Z, Yu R, Zuo F, Zhang B, Peng D, Ma H, et al. (2016) Heterologous Expression and Delivery of Biologically Active Exendin-4 by Lactobacillus paracasei L14. PLoS ONE 11(10): e0165130. https://doi.org/10.1371/journal.pone.0165130

Editor: Hélder A. Santos, Helsingin Yliopisto, FINLAND

Received: July 5, 2016; Accepted: October 6, 2016; Published: October 20, 2016

Copyright: © 2016 Zeng et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: All relevant data are within the paper and its Supporting Information files.

Funding: This work was supported by the National Science and Technology Support Program of the People’s Republic of China (2011BAD09B03). The funder Yangling Zhongyang Joint Ranch Co., Ltd. provided study materials for us, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.

Competing interests: The Yangling Zhongyang Joint Ranch Co., Ltd. provided study materials for us. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.

Introduction

Glucagon-like peptide-1 (GLP-1) is a potent incretin produced by L-cells of the distal ileum and colon in response to nutrient intake [1]. It has a variety of antidiabetic effects that are mediated through β-cells in pancreatic islets and peripheral tissues. These include not only the promotion of glucose-dependent insulin secretion and inhibition of glucagon secretion [2, 3], but also inhibition of food intake and body weight gain by delaying gastric emptying [3], increasing β-cell mass [4, 5], and enhancing insulin sensitivity [6, 7]. However, despite its favorable antidiabetic functions, the native form of GLP-1 is unsuitable for therapeutic use because of its extremely short half-life in vivo (~1–2 min), due to its rapid inactivation by the ubiquitous enzyme dipeptidyl peptidase IV (DPP-IV) [8]. Two GLP-1-based strategies have been adopted to solve this problem: DPP-IV-resistant GLP-1 analogs and DPP-IV inhibitors [9]. Sitagliptin, saxagliptin and vildagliptin are examples of currently available DPP-IV inhibitors. Their major advantage is that they can be administered orally; however, many other hormones are also substrates of DPP-IV, and DPP-IV inhibition may affect the pathways mediated by those hormones [10].

Exendin-4, the first discovered GLP-1 mimetic (with 53% homology), was originally isolated from the salivary secretions of the Gila monster Heloderma suspectum [11]. Exendin-4 binds to and activates the GLP-1 receptor, and thus shares many antidiabetic actions with GLP-1, such as glucose-dependent increase of insulin secretion, suppression of glucagon secretion, reduction of food intake and facilitation of β-cell neogenesis [12–15]. Exendin-4 has a longer biological half-life than GLP-1 due to its resistance to DPP-IV degradation, and can serve as a potent and longer-acting agonist of the pancreatic GLP-1 receptor [16]. Synthetic exendin-4 (exenatide) was approved as the first GLP-1 receptor agonist for diabetes treatment by the US Food and Drug Administration (FDA) in 2005. Today, an exenatide extended-release suspension (Bydureon) is available, administered by weekly injection [17].

Oral administration is the preferred method of drug delivery due to patient acceptance, long-term compliance and few side effects [18, 19]. However, this strategy is usually not feasible for protein or peptide drugs due to poor bioactivity resulting from proteolysis during passage though the gastrointestinal environment and poor epithelial permeability [20]. Many approaches have been explored to increase the oral bioavailability of antidiabetic peptides by protecting them from enzymatic digestion and increasing their absorption across the intestinal wall [19, 20]. Some of the most widely studied strategies include the use of nanoparticles [20, 21], mucoadhesive polymers [22], absorption enhancers [23] and oral films [24]. Although these strategies have provided novel prospects for the problem, most of them have encountered roadblocks such as low efficacy and high toxicity, and have barely advanced to clinical trials [25].

In the past two decades, lactic acid bacteria (LAB) have been demonstrated as promising oral delivery vehicles for protein/peptide drugs [26–28]. Before that, LAB were used for centuries in traditional fermented products in the food industry; they are generally regarded as safe (GRAS) by the FDA. In addition, specific strains of LAB, and especially of Lactobacillus, have many intrinsic probiotic effects on human and animal health, such as maintaining gastrointestinal homeostasis and modulating immunity [29]. Furthermore, many Lactobacillus strains can survive transit through the human gastrointestinal tract and tightly adhere to the intestinal epithelial cells, facilitating mucosal targeting and transport of therapeutic molecules while minimizing bacterial and enzymatic degradation of the protein-based drugs [30, 31]. Because of these advantages, LAB have been regarded as an appealing potential alternative to other oral delivery systems. A study on the use of interleukin (IL)-10-transformed Lactococcus lactis to treat Crohn’s disease has passed phase I clinical trials [32]. Several articles exploring the potential of transformed LAB for diabetes treatments have also been published, including the use of L. lactis to deliver insulin analog [33–35] or combined expression of IL-10 and glutamic acid decarboxylase (GAD65) [36], and the use of Bifidobacterium longum to deliver GLP-1 [37] or Lactobacillus gasseri to deliver GLP-1(1–37) [38]. Here, we evaluated whether Lactobacillus paracasei can secrete bioactive exendin-4, to provide an alternative route for the use of LAB as a vector for oral delivery of exendin-4.

In this study, a L. paracasei strain transformed for expression and secretion of bioactive exendin-4 was explored as a novel delivery system for this GLP-1 mimetic. The expression characteristics of exendin-4 in L. paracasei were assayed and the bioactivities of recombinant exendin-4 were evaluated on the in vitro pancreatic β-cell line INS-1 as a model. The transport of exendin-4 through intestinal epithelial cells was also assayed using Caco-2 cell monolayers in vitro.

Materials and Methods

Materials

The Caco-2 cell line and the rat insulinoma cell line INS-1were purchased from American Type Culture Collection. Dulbecco’s modified eagle medium (DMEM), Roswell Park Memorial Institute medium (RPMI) 1640, fetal bovine serum (FBS), non-essential amino acids (100X), and 0.25% trypsin with EDTA were obtained from Gibco BRL Life Technology. Transwell^® inserts, treated tissue culture (0.4 μm pore size, 4.7 cm² surface area) and culture flasks were purchased from Costar Corporation (Corning, NY).

Bacterial strains, plasmids, and growth conditions

The bacterial strains and plasmids used in this study are listed in Table 1. Escherichia coli strains were grown at 37°C in Luria-Bertani (LB) medium with shaking at 200 rpm. L. paracasei L14 was aerobically propagated statically at 37°C in de Man, Rogosa and Sharpe (MRS) medium. Antibiotics were used at the following concentrations: 500 μg/ml erythromycin or 100 μg/ml ampicillin for E. coli and 5 μg/ml erythromycin for lactobacilli.

Download:

Table 1. Bacterial strains and plasmids used in this study.

https://doi.org/10.1371/journal.pone.0165130.t001

DNA manipulation and transformation

The exendin-4 cDNA sequence was obtained from GenBank (DI206426.1) and was codon optimized for LAB using the Codon Adaptation Tool (JCAT). An oligonucleotide carrying a fusion of signal peptide Usp45 and LEISSTCDA propeptide sequences, exendin-4, 6×His tag and Xba I and Xho I cDNA restriction sites between Usp45 and the 6×His tag was synthesized by GENEWIZ Biological Technology Co. Ltd. (Suzhou, China). This was incorporated into pMG76e vector (derived from pMG36e [39]) to yield pMG76e-exendin-4. The pMG76e-exendin-4 and empty control pMG76e plasmids were transformed into competent L. paracasei L14 cells by electroporation.

Heterologous expression and secretion of exendin-4 by L. paracasei L14

To detect exendin-4 expression, the recombinant L. paracasei L14/pMG76e-exendin-4 and control (L. paracasei L14/pMG76e) transformants were grown overnight in MRS medium supplemented with 5 μg/ml erythromycin. A 1% (v/v) inoculum of the L. paracasei transformants was transferred into 50 ml fresh MRS medium and incubated statically at 37°C for 12 h; 100 μl of culture supernatant was sampled every 2 h for ELISA assay of exendin-4 secretion.

To prepare exendin-4-conditioned medium for INS-1 cell experiments, RPMI 1640 medium was used for exendin-4 secretion (RPMI 1640–exendin-4 medium). Overnight cultures of L. paracasei L14/pMG76e-exendin-4 and L. paracasei L14/pMG76e were diluted 1:100 in fresh MRS medium and incubated at 37°C for 12 h, to a bacterial cell density of about 10⁹ cfu/ml. Cells were then harvested and washed twice in PBS (pH 7.4) buffer, suspended in RPMI 1640 buffered with 20 mM HEPES (pH 7.4), and incubated for 12 h. The culture was centrifuged at 8000 × g for 10 min at 4°C. The supernatant was collected, adjusted to pH 7.4 with sodium hydroxide, and sterilized by filtration through a 0.22-μm membrane as RPMI 1640–exendin-4 medium.

Recombinant exendin-4 extraction and western blot analysis

The transformed L. paracasei L14 strain cultures (10 ml of 10⁹ or 10¹⁰ cfu/ml cells) were centrifuged at 6000 × g for 10 min at 4°C. Soluble cytoplasmic and secreted protein fractions were respectively prepared. The cell pellets were washed three times with PBS, resuspended in 1 ml PBS buffer (pH 7.4) and ultrasonically disrupted. Cell debris were separated out by centrifugation and discarded. The supernatant was subjected to precipitation with trichloroacetic acid (10% w/v) for 2 h at 4°C; then the mixture was centrifuged at 12,000 × g for 10 min, and the pellet was washed three times with ice-cold acetone and then dissolved in 50 μl PBS. Both cytoplasm and medium extract samples were mixed with 4× SDS loading buffer (12% w/v SDS, 6% v/v β-mercaptoethanol, 30% w/v glycerol, 0.05% w/v Coomassie blue G-250, 150 mM Tris-HCl pH 7.0), and subjected to Tricine SDS-PAGE (16% T, 6% C) analysis as described previously [40]. Proteins on the polyacrylamide gel were then semi-dry-electrotransferred to a PVDF membrane (Millipore). The 6×His-tagged exendin-4 proteins were analyzed by Western blotting with 6×His antibody (Cell Signaling Technology), horseradish peroxidase-conjugated goat anti-rabbit polyclonal IgG secondary antibody (Cell Signaling Technology) and the ECL Chemiluminiscent Substrate (Pierce) according to manufacturer's instructions.

Indirect ELISA quantification of secreted exendin-4

The concentration of exendin-4 secreted by recombinant L. paracasei was measured by indirect ELISA according to the method described by Zhang et al. [41] with some modifications. Standard exendin-4 (Sigma, 0.2 μg/ml) was used as the coated antigen. Equal volumes (100 μl) of monoclonal antibody against exendin-4 (Abcam) (1:4000) and standard exendin-4 (0–100 nmol/l) or culture supernatant samples of L. paracasei L14/pMG76e-exendin-4, preincubated overnight at 4°C, were applied to detect the captured exendin-4. Horseradish peroxidase-conjugated rabbit anti-mouse IgG (Abcam) (100 μl) was used at a 1:10,000 dilution and revealed by reaction with TMBS substrate (Amresco). Absorption was determined at 450 nm and 630 nm by Multiskan MK3 ELISA plate reader (Thermo Labsystems). The exendin-4 concentration was calculated by the standard curve method.

Cell culture of rat insulinoma cell line INS-1

INS-1 cells (passage 10–20) were cultured in RPMI 1640 medium containing 10% (v/v) FBS, 1 mM sodium pyruvate, 50 μM β-mercaptoethanol, 10 mM HEPES, 100 U/ml penicillin and 100 μg/ml streptomycin, and cells were maintained at 37°C in a humidified (5% CO₂, 95% air) atmosphere.

Insulin secretion assay

INS-1 cells were seeded in 24-well plates at a density of 10⁵ cells per well and grown to 100% confluence before the assay. The medium was changed 24 h before the assay. For the assay, cells were quickly rinsed in 1 ml Hank's balanced salt solution (HBSS) [42] with 3 mM glucose followed by a 2 h preincubation with 1 ml of the same buffer. Then the buffer was discarded, RPMI 1640–exendin-4 medium diluted 1:1 (v/v) with fresh medium plus 5 mM glucose (600 μl per well) were added, and the mixture was incubated for 2 h. Standard GLP-1 (100 nmol/l) in RPMI 1640 medium was used as a positive control. Preliminary experiments indicated that 5 mM glucose maximizes glucose-dependent insulin secretion of INS-1 cells stimulated by GLP-1 (S1 Fig). At the end of the incubation, supernatant was collected and centrifuged for 10 min at 4000 × g at 4°C and insulin concentration was determined by ELISA kit (Millipore, St. Charles, MO, USA). The cells were collected to analyze mRNA expression of pancreatic duodenal homeobox-1 (PDX-1) and insulin gene (Insulin).

Quantitative reverse transcription PCR (qRT-PCR) analysis of expression of PDX-1 and Insulin

Total RNA was isolated from INS-1 cells using TRIzol Reagent (Invitrogen). Reverse transcription was performed using PrimeScript II first-strand cDNA synthesis kit (Takara, China), containing 1 μg of total RNA as the template. qRT-PCR was carried out using a SYBR Green assay kit (Tiangen). Specific primers for PDX-1, Insulin and the internal control gene β-actin (Actb) from Rattus norvegicus were designed with Primer Premier 5 software (Table 2). Gene expression was normalized by the ΔΔC_T method [43] using β-actin as the reference for the calculations. The experiment was carried out in triplicate and the average results are reported.

Download:

Table 2. Primers used in this study.

https://doi.org/10.1371/journal.pone.0165130.t002

Cell-proliferation and apoptosis assay

INS-1 cells were seeded in 96-well plates at a density of 2 × 10⁴ cells per well. After 36 h incubation, the cells were grown to nearly 60% confluence and the medium was replaced with RPMI 1640–exendin-4 medium diluted 1:1 (v/v) with fresh RPMI 1640 containing 10% FBS (100 μl per well). Standard GLP-1 in RPMI 1640 medium (100 nmol/l) was used as a positive control and pure RPMI 1640 medium was used as a blank control. The mixture was incubated for 24 h. The PI3K (phosphatidylinositol-3-kinase) antagonist treatment cells were preincubated with wortmannin (100 nmol/l) for 15 min before the treatment. The number of viable cells was then analyzed by cell counting kit-8 (CCK-8) assay (Biyuntian Biotech Co. Ltd.) based on the formation of formazan with sensitive changes in OD₄₅₀ values. Briefly, at the end of the 24-h incubation, the medium was discarded and cells were washed twice in RPMI 1640 and incubated in a 100-μl mixture (with 90 μl RPMI 1640 and 10 μl CCK-8) in each well for 4 h. The absorbance was read at 450 nm using a Multiskan MK3 ELISA plate reader to determine the in vitro cell proliferation. For apoptosis assays, staurosporine (1 μmol/l) was added in all treatment groups for 1 h, after which the cells were treated with Annexin V-PI (propidium iodide) cell apoptosis kit (Biyuntian Biotech Co. Ltd.) and apoptosis was measured by flow cytometry using a FACScan (Becton Dickinson).

Transport of exendin-4 through Caco-2 monolayer

Caco-2 cells (10–20 passages) were cultivated in 25-cm² flasks in DMEM supplemented with 10% (v/v) FBS, 1% (v/v) non-essential amino acids and 100 IU/ml penicillin–100μg/ml streptomycin (s-DMEM) at 37°C in an atmosphere of 5% CO₂ and high humidity. Upon 80% confluence, cells were harvested using 0.25% trypsin EDTA and seeded on the polyester inserts (0.4 μm pore size, 24 mm diameter, 4.67 cm² grown surface, Costar, Corning, NY) in 6-well transwell plates at a density of 10⁵ cell/cm² and incubated under normal cell culture conditions. The culture medium was replaced every other day for the first week and then every day until it was ready for transport studies when the monolayer became confluent and the transepithelial electrical resistance (TEER) reading reached a plateau (about 21 days). The TEER was monitored according to the method described by Hubatsch et al [44].

After the Caco-2 monolayer cell became confluent, the culture medium was washed twice by PBS (pH 7.4). Then 1.5 ml of freshly made L14/pMG76e-exendin-4 cells in antibiotic-free s-DMEM (~10⁸ cfu/ml) was added to the apical side and 2.6 ml of fresh s-DMEM without antibiotics was added to the basolateral side. Caco-2 cell viability was then measured by trypan blue assay at 0, 2, 4 and 6 h after the addition of L14/pMG76e-exendin-4 cells. To assay exendin-4 transport through the Caco-2 monolayer, the plate was centrifuged at 45 × g for 5 min after the bacterial cells were added and incubated under normal culture conditions. At predetermined time points, 100 and 200 μl supernatant samples were withdrawn from the apical and basolateral sides, respectively, for exendin-4 quantification by ELISA and replaced with an equal volume of s-DMEM without the antibiotics. The normalized transport rate of exendin-4 was calculated according to Agarwal et al. [35], and TEER was monitored as well.

Statistical analysis

All experiments were performed in triplicate, and data were expressed as mean ± SD. All analyses were carried out by one-way ANOVA and significant differences (P < 0.05) between means were identified by Duncan’s test using SPSS 20 (SPSS Inc.).

Results

Expression of recombinant exendin-4 in L. paracasei L14

Fig 1 shows the plasmid pMG76e-exendin-4 and the cDNA sequence of the codon-optimized exendin-4. The constructed plasmids pMG76e and pMG76e-exendin-4 were introduced into L. paracasei L14 and the resultant transformant culture and cells were prepared for the assays. Soluble cytoplasmic and secreted protein fractions were extracted from cells and culture media and subjected to Tricine SDS-PAGE and immunoblotting assays (Fig 2). Fig 2A shows the western blot analysis of recombinant exendin-4 of transformed strains cultured in MRS medium. A prominent 9.4-kDa band can be seen in the supernatants of both the bacterial culture and the soluble cytoplasmic proteins from recombinant strain L. paracasei L14/pMG76e-exendin-4. This band matched the calculated molecular weight corresponding to the primary protein, containing the signal peptide Usp45 of the recombinant exendin-4. Thus, the signal peptide in the MRS supernatant could not be cleaved by L. paracasei signal peptidase.

Download:

Fig 1. Expression cassette for recombinant exendin-4 secretion by L. paracasei strain L14.

Expression of the recombinant exendin-4 was controlled by the constitutive p32 promoter. SP_Usp45: sequence encoding the signal peptide Usp45; LEISSTCDA: sequence encoding the synthetic LEISSTCDA propeptide; the codon-optimized cDNA sequence of exendin-4 is also supplied.

https://doi.org/10.1371/journal.pone.0165130.g001

Download:

Fig 2. Western blotting and enzyme-linked immunosorbent assay (ELISA) analysis of recombinant exendin-4 produced by plasmid-transformed L. paracasei L14 strains.

(a) Strains cultured in MRS medium: lanes 1 and 2, cell pellet of L. paracasei L14/pMG76e and L. paracasei L14/pMG76e-exendin-4 strains, respectively; lanes 3 and 4, excretion of L. paracasei L14/pMG76e and L. paracasei L14/pMG76e-exendin-4 strains, respectively. (b) Strains cultured in buffered RPMI 1640 medium: lanes 1 and 2, cell pellet extraction of L. paracasei L14/pMG76e-exendin-4 strain with bacterial concentration of 10⁹ cfu/ml and 10¹⁰ cfu/ml, respectively; lanes 3 and 4, cell excretion of L. paracasei L14/pMG76e-exendin-4 strain with bacterial concentration of 10⁹ cfu/ml and 10¹⁰ cfu/ml, respectively. (c) ELISA of exendin-4 expression in vitro at different time points of culture as described in the methods (three repeat expressions, means ± SD).

https://doi.org/10.1371/journal.pone.0165130.g002

RPMI 1640 medium buffered with 20 mM HEPES (pH 7.4) was conditioned with the transformant strain of L. paracasei L14/pMG76e-exendin-4 and used at different bacterial cell concentrations (10⁹ cfu/ml and 10¹⁰ cfu/ml) to secrete exendin-4. The secreted exendin-4 showed multiple proteoforms (Fig 2B): a preprotein of 9.4 kDa was found in the soluble cytoplasmic fraction, and two protein bands, the 9.4-kDa preprotein and the mature 5.1-kDa protein with successful cleavage of the signal peptide, appeared in supernatants of the transformed strain. The bacteria at 10¹⁰ cfu/ml produced more recombinant exendin-4 than bacteria at 10⁹ cfu/ml, indicating that exendin-4 expression and secretion levels are positively related to bacterial density. Prolonged incubation of the transformed L. paracasei strain in buffered RPMI 1640 medium produced mature exendin-4, implying that buffered RPMI 1640 medium may provide a more suitable biochemical environment for correct sorting and processing of secreted exendin-4 by the bacterial signal peptidases.

Fig 2C shows the growth curve of the transformed strain, L. paracasei L14/pMG76e-exendin-4, and its secretion of exendin-4. The secretion of exendin-4 by L. paracasei L14/pMG76e-exendin-4 was consistent with the bacterial growth profile. Total secretion of exendin-4 reached 28.5 nmol/l in 50 ml culture volume after 12 h incubation.

Recombinant exendin-4's insulinotropic effect in INS-1 cells

To determine whether the exendin-4 protein secreted by L. paracasei L14/pMG76e-exendin-4 retains its biological activity, its ability to stimulate insulin secretion was evaluated with rat pancreatic β-cell line INS-1. As observed in Fig 3, L. paracasei L14/pMG76e–exendin-4 medium significantly stimulated insulin secretion to 69.1 ± 0.3 ng/ml, which was 4% higher than the blank control (with only RPMI 1640, 66.5 ± 0.5 ng/ml, added) (p < 0.05), and 5% higher than the negative control (L. paracasei L14 with empty plasmid pMG76e-conditioned medium, 65.9 ± 0.8 ng/ml) (p < 0.05). Similarly prepared medium from L. paracasei L14 transformed with empty plasmid pMG76e failed to increase insulin secretion. The GLP-1 standard solution also displayed insulinotropic ability, which enhanced insulin secretion to 71.4 ± 0.7 ng/ml, 7% higher than the blank control (p < 0.05). Thus, it could be concluded that the Lactobacillus-secreted exendin-4 is bioactive and has an insulinotropic effect.

Download:

Fig 3. Effect of recombinant exendin-4 on insulin secretion of INS-1 cells (means ± SD, n = 3).

*p < 0.05 vs. control cells with pure cell culture media; ^##p < 0.01 vs. L. paracasei L14/pMG76e-treated group.

https://doi.org/10.1371/journal.pone.0165130.g003

Recombinant exendin-4 increases mRNA expression of PDX-1 and the insulin gene

PDX-1 is an important transcription factor, which plays an essential role in GLP-1-enhanced insulin transcription and synthesis, pancreas development and β-cell neogenesis [45–47]. GLP-1 can increase pancreatic expression of PDX-1, enhancing the transcription and synthesis of insulin [47]. Thus, we also investigated mRNA expression levels of PDX-1 and the insulin gene in INS-1 cells treated with RPMI 1640–exendin-4 medium for 2 h. As shown in Fig 4A, L. paracasei L14/pMG76e–exendin-4 medium significantly increased PDX-1 mRNA expression (p < 0.01), which was 2.2-fold higher than in the blank control and 1.8-fold higher than in L. paracasei L14/pMG76e medium. The GLP-1 standard solution also increased PDX-1 mRNA expression to 1.9-fold that of the blank control. Insulin mRNA expression was consistent with that of PDX-1 (Fig 4B). L. paracasei L14/pMG76e–exendin-4 medium increased insulin mRNA expression 1.5-fold (p < 0.01) and 1.6-fold (p < 0.01) that of the blank control and L. paracasei L14 harboring empty plasmid, respectively. The standard GLP-1 also promoted insulin gene transcription (p < 0.01), which was 1.7-fold higher than the blank control. Taken together, these results suggested that the expression of PDX-1 is upregulated by L. paracasei L14-secreted exendin-4, thereby exerting the functional effects of enhancing insulin transcription and synthesis.

Download:

Fig 4. Effect of recombinant exendin-4 on the transcription of PDX-1 and insulin gene in INS-1 cells.

(a) PDX-1 mRNA expression level (means ± SD, n = 3). (b) Insulin mRNA expression level (means ± SD, n = 3). **p < 0.05 vs. control cells with pure cell culture media and L. paracasei L14/pMG76e-treated group.

https://doi.org/10.1371/journal.pone.0165130.g004

Recombinant exendin-4 enhances INS-1 cell proliferation and decreases staurosporine-induced cell apoptosis

GLP-1, and its long-acting analog exendin-4, can also increase proliferation and decrease apoptosis of β-cells [4, 48]; both of these effects are prevented by treatment with wortmannin, a specific pharmacological inhibitor of PI3K [4]. Therefore, we determined whether the exendin-4 secreted by L. paracasei is also functionally involved in regulating proliferation and apoptosis of β-cells using the INS-1 cell model. As shown in Fig 5A, both conditioned media—with pMG76e and pMG76e-exendin-4 transformant culture—inhibited INS-1 cell growth compared to the blank control group. However, compared to pMG76e, pMG76e-exendin-4 transformant-conditioned medium significantly increased cell proliferation (p < 0.01), by 13.5%. On the other hand, when wortmannin was added, there was no significant difference in cell proliferation between the pMG76e and pMG76e-exendin-4 treatments, indicating that the recombinant exendin-4 improves INS-1 cell proliferation via the PI3K signal pathway. The positive control, 100 nmol/l standard GLP-1, also increased cell proliferation (p < 0.05), which was 15.3% higher than with the blank control.

Download:

Fig 5. Effect of recombinant exendin-4 on proliferation and staurosporine-induced apoptosis of INS-1 cells.

(a) INS-1 cells were preincubated with media alone or with 100 nmol/l wortmannin, followed by treatment with different agents as indicated for 18 h (means ± SD, n = 3). *p < 0.05 vs. control cells with pure cell media; ##p < 0.01. (b) INS-1 cells were preincubated with media alone or with 100 nmol/l wortmannin, followed by treatment with different agents as indicated for 18 h. Then cells were treated with media or 1 mmol/l staurosporine, as indicated (means ± SD, n = 3). **p < 0.01 vs. control cells with no staurosporine; #p < 0.05 vs. cells with only staurosporine; ^$ $p < 0.01.

https://doi.org/10.1371/journal.pone.0165130.g005

After a 1 h treatment with staurosporine, a general kinase inhibitor which induces a broad spectrum of cell apoptosis [49, 50], the number of earliest-stage apoptotic cells was significantly increased to 264.3% of the control with no staurosporine (p <0.01); pretreatment with standard GLP-1 reduced the apoptosis to 170% (p < 0.05) (Fig 5B). The number of earliest-stage apoptotic cells was 582% of the control upon pretreatment with pMG76e culture, while the number was significantly reduced to 376% (p < 0.01) when pretreatment was with pMG76e-exendin-4 culture. When wortmannin was added, apoptotic cell number following pMG76e-exendin-4 treatment was 562%, not significantly different from the pMG76e treatment. These results showed that the exendin-4 secreted by L. paracasei L14 decreases staurosporine-induced apoptosis via the PI3K signal pathway.

Delivery of exendin-4 by L14/pMG76e-exendin-4 through Caco-2 cell monolayer

The effect of L14/pMG76e-exendin-4 on cell viability in the Caco-2 monolayer was analyzed by the trypan blue method. As shown in Fig 6A, cell viability was 100, 99 and 98% at 2, 4 and 6 h compared to no treatment, respectively. Differences in Caco-2 cell viability in the absence vs. presence of L14/pMG76e-exendin-4 were not significant (p >0.05).

Download:

Fig 6. Transport of exendin-4 through Caco-2 cell monolayers.

(a) Caco2 cell viability when co-cultured with strain L14/pMG76e-exendin-4. (b) TEER values of the Caco-2 cell monolayer in the presence of L14/pMG76e-exendin-4 or standard exendin-4 solution (control) during the exendin-4 transport study (means ± SD, n = 3). L14/pMG76e-exendin-4 suspension in s-DMEM or standard exendin-4 in s-DMEM was added to the apical side of all wells and incubated for 6 h. (c) Transport of exendin-4 across the Caco-2 monolayers (means ± SD, n = 3). Samples from both the apical and basolateral side of the transwell were taken for the assay of exendin-4 concentration by ELISA (means ± SD, n = 3). (d) Normalized transport rate of exendin-4 through Caco-2 monolayers (means ± SD, n = 3).

https://doi.org/10.1371/journal.pone.0165130.g006

TEER was monitored to explore the integrity of the Caco-2 cell monolayer throughout the experimental period. As shown in Fig 6B, during the transport studies, the TEER values were nearly stable and there was no statistical difference between the wells in the presence or absence of L14/pMG76e-exendin-4, indicating that the integrity of the cell monolayer was not compromised.

Fig 6C shows the absorption of exendin-4 through the Caco-2 monolayer when delivered by the transformed strain L14/pMG76e-exendin-4 or standard exendin-4 solution (control). During the first 3 h, the exendin-4 transport rates through the cell monolayer was 0.18 ± 0.002 and 0.15 ± 0.013 pMol cm^-2 h^-1 for L14/pMG76e-exendin-4 and the standard exendin-4, respectively. However, from 3–6 h, the transport rate of L14/pMG76e-exendin-4-delivered exendin-4 reached 2.5 ± 0.45 pMol cm^-2 h^-1 (Fig 6D), which was 34 times that of the exendin-4 control, indicating that the living L. paracasei delivery system has a much higher efficiency for exendin-4 absorption and transportation. This high delivery efficiency is probably due to the bacteria's strong adherence to the monolayer surface leading to an increased concentration of exendin-4 close to the epithelial cell monolayer [31, 51].

Discussion

Exendin-4, a long-acting agonist of the GLP-1 receptor, shares many antidiabetic actions with GLP-1, and has become an important therapeutic drug for diabetes. However, subcutaneous injection is still the common administration route for such peptide drugs.

In this study, we developed a novel oral delivery system for exendin-4 by using an engineered Lactobacillus strain as the carrier. Lactobacilli, as the major inhabitants of the human intestinal tract, can reach and colonize the intestine and play an important role in maintaining a healthy microbiota, as well as contributing to many beneficial functions for human health [29]. These properties make lactobacilli better candidates as live oral vectors for mucosal delivery of prophylactic and therapeutic molecules than Lactococcus lactis. We developed recombinant L. paracasei as an oral vector for the live delivery of exendin-4 in situ, taking advantage of its probiotic colonization of the intestinal tract.

To guarantee an engineered strain of L. paracasei L14 with considerable exendin-4 secretion, the Usp45 signal peptide and LEISSTCDA were concatenated as the signal and leading peptides of recombinant exendin-4 [52] (Fig 1). Western blot confirmed expression of the exendin-4 proprotein in both supernatant and cells of the bacteria (Fig 2A); cleavage of the recombinant signal peptide, yielding mature exendin-4 with the expected molecular mass of 5.1 kDa, was obtained from the proteoforms of exendin-4 under the proper pH conditions (Fig 2B), due to the putative influence of medium pH on the processing of the secreted recombinant protein. When grown in MRS medium for 12 h, L. paracasei L14 acidifies the growth medium to pH 4.0–4.6, whereas when it is grown in buffered RPMI 1640 medium for 12 h, the pH value is maintained at 6.0–7.4. Previous studies have suggested that culture pH is an important factor in regulating secreted recombinant protein for correct sorting, processing, and maintenance of stability and bioactivity. It was further revealed that an acid environment decreases the stability and bioactivity of secreted proteins [33, 53, 54,]. Thus, we hypothesize that the mature exendin-4 develops in buffered RPMI 1640 medium primarily because its near-neutral pH leads to better protein processing. In addition, studies have reported that lactobacilli reside mainly in the human ileum, jejunum, and colon [55, 56], which have pH values of about 6.0–8.0 [57]. These values are close to that of the buffered RPMI 1640 medium in which the mature exendin-4 developed.

Quantification assay showed secretion of 28.5 nmol/l exendin-4 after 12 h (Fig 2C). When co-cultured with Caco-2 cells, total secretion of exendin-4 reached 70.4 pMol/10⁸ cfu within 6 h following a linear increment, and about 51% of this was absorbed and transported by the Caco-2 cell monolayer (Fig 6C). The secreted and processed exendin-4 protein had an insulinotropic effect on the rat pancreatic islet β-cell line INS-1, comparable to the positive control (100 nmol/l GLP-1) (Fig 3). The GLP-1 analog exendin-4 is known to have important antidiabetic effects, mainly through promotion of insulin secretion and insulin synthesis via upregulation of PDX-1 gene expression [47, 58], facilitation of β-cell neogenesis and inhibition of β-cell apoptosis [15]. Our results indicated that the secreted exendin-4 retains biological activity for enhancement of β-cell insulin secretion and synthesis, which is related to the PDX-1-dependent pathway (Figs 3 and 4). Increased β-cell proliferation and inhibition of β-cell apoptosis were also observed (Fig 5). As displayed in Fig 5, L. paracasei L14 harboring exendin-4 significantly stimulated cell proliferation and decreased cell apoptosis compared to the strain harboring the empty vector pMG76e. In contrast, when the inhibitor wortmannin was added, there was no significant difference in either cell proliferation or apoptosis following treatment with L14/pMG76e-exendin-4 vs. L14/pMG76e. This proves that the biological activity of recombinant exendin-4 is in fact through the GLP-1 receptor pathway, which comprises the PI3K signaling pathway when exendin-4 is delivered by the L. paracasei L14 strain. Compared to the blank control (only cell media), L. paracasei L14 harboring pMG76e and pMG76e-exendin-4 both inhibited cell growth. This could be due to inhibition by L. paracasei L14 itself. Several studies have reported that probiotic lactic acid bacteria have anticancer effects on cancer cells but have no cytotoxicity toward normal cells [59, 60]. Since INS-1 is a rat insulinoma cell line, inhibition due to L. paracasei's anticancer effects is a reasonable assumption. Taken together, our results demonstrate that the engineered strain L. paracasei L14/pMG76e-exendin-4 can efficiently express and secrete the recombinant exendin-4, and by in situ delivery, transform the target protein into biologically active exendin-4, as a GLP-1 receptor agonist.

The Caco-2 cell line, a widely used intestinal model for predicting in vivo intestinal drug absorption [61], was used to model for the transport of secreted exendin-4 in vitro. The transport rate of exendin-4 delivered by L14/pMG76e-exendin-4 was 34-fold higher than that of the exendin-4 solution from 3–6 h of the experimental period (Fig 6D). Our results are in accordance with previous studies in which the transport rate of GLP-1 was increased by eight times and that of β-lactamase was doubled by L. lactis delivery [35, 51]. The concentration of exendin-4 on the Caco-2 monolayer may be an important reason for the absorption enhancement. Since the L. paracasei strain shows strong adhesion to the monolayer, it can secrete exendin-4 directly onto the apical surface of the monolayer and result in a locally high concentration gradient.

This study represents a novel trial for the use of L. paracasei as a system for oral delivery of exendin-4 for diabetes treatment. As such, it opens up the possibility of oral exendin-4 delivery using live food-grade microorganisms. Many studies have reported that probiotics can control diabetes by improving insulin resistance and alleviating hyperglycemia [62–64]. L. paracasei L14 was isolated from traditional dairy products, with natural and safe properties, and our previous study also showed that it possesses DPP-IV-inhibitory activity [65] and strong adhesive capacity for intestinal epithelial HT-29 cells, 3.2-fold that of Lactobacillus rhamnosus GG. Thus, the recombinant L. paracasei L14 can colonize the intestinal mucosa and continuously express and deliver the peptide drug in situ for long periods. This is desirable and important for diabetes and other chronic diseases. The constitutive p32 promoter used here can maintain the expression of exendin-4 in a cell density-dependent manner without the aid of any expression inducer, such as nisin, after oral administration.

Although the present study shows that L. paracasei can secrete bioactive exendin-4 and significantly increases the transport of exendin-4 through Caco-2 monolayers, this is only an initial step in exploring the possibility of oral exendin-4 delivery by L. paracasei. Some issues still need to be addressed before clinical trials, such as the efficacy of in vivo delivery, control of the dose of recombinant protein for the desired effect, and potential environmental pollution by the engineered bacteria when eliminated from the body.

Conclusions

The present work demonstrates that, when transformed by a plasmid, probiotic L. paracasei can be a live delivery vector for the peptide drug exendin-4. Using lactobacilli as delivery vectors for diabetes treatment opens up the possibility of oral exendin-4 delivery using live food-grade microorganisms. Further investigations into the biological activity of the engineered Lactobacillus strain in vivo are therefore warranted.

Supporting Information

S1 Fig. The effect of glucose concentration on GLP-1-stimulated insulin secretion from INS-1 cells.

Cells were cultured in media with different concentrations of glucose with or without GLP-1 for 2 h, and then insulin concentration was assayed. Medium with 3 mM glucose was used as a control. Data represent the means ± SD of three independent experiments.

https://doi.org/10.1371/journal.pone.0165130.s001

(TIF)

Author Contributions

Conceptualization: ZZ SC.
Formal analysis: ZZ HM.
Funding acquisition: SC.
Investigation: ZZ RY FZ BZ.
Methodology: ZZ.
Project administration: SC.
Resources: SC DP.
Supervision: SC.
Validation: ZZ SC.
Writing – original draft: ZZ.
Writing – review & editing: ZZ SC.

References

1. Drucker DJ. Glucagon-like peptides. Diabetes. 1998; 47: 159–169 pmid:9519708
- View Article
- PubMed/NCBI
- Google Scholar
2. Nauck MA, Wollschlager D, Werner J, Holst JJ, Ørskov C, Creutzfeldt W, et al. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7–36 amide]) in patients with NIDDM. Diabetologia. 1996; 39: 1546–1553 pmid:8960841
- View Article
- PubMed/NCBI
- Google Scholar
3. Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA. Gastric emptying, glucose responses and insulin secretion after a liquid test meal: Effects of exogenous glucagon-like peptide-1 (GLP-1)-(7–36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab. 1996; 81: 327–332 pmid:8550773
- View Article
- PubMed/NCBI
- Google Scholar
4. Wang Q, Li L, Xu E, Wong V, Rhodes C, Brubaker PL. Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells. Diabetologia. 2004; 47: 478–487 pmid:14762654
- View Article
- PubMed/NCBI
- Google Scholar
5. Verspohl EJ. Novel therapeutics for type 2 diabetes: Incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Therapeut. 2009; 124: 113–138
- View Article
- Google Scholar
6. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet. 2002; 359: 824–830 pmid:11897280
- View Article
- PubMed/NCBI
- Google Scholar
7. Sarkar G, Alattar M, Brown RJ, Quon MJ, Harlan DM, Rother KI. Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes. Diabetes Care. 2014; 37: 666–670 pmid:24194508
- View Article
- PubMed/NCBI
- Google Scholar
8. Holst JJ, Deacon CF. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes. 1998; 47: 1663–1670 pmid:9792533
- View Article
- PubMed/NCBI
- Google Scholar
9. Neumiller JJ. Incretin-based therapies. Med Clin North Am. 2015; 99(1): 107–129 pmid:25456646
- View Article
- PubMed/NCBI
- Google Scholar
10. Mest HJ, Mentlein R. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes. Diabetologia. 2005; 48(4): 616–620 pmid:15770466
- View Article
- PubMed/NCBI
- Google Scholar
11. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem. 1992; 267: 7402–7405 pmid:1313797
- View Article
- PubMed/NCBI
- Google Scholar
12. Edwards CM, Stanley SA, Davis R, Brynes AE, Frost GS, Seal LJ, et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab. 2001; 281: E155–E161 pmid:11404233
- View Article
- PubMed/NCBI
- Google Scholar
13. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea treated patients with type 2 diabetes. Diabetes Care. 2004; 27: 2628–2635 pmid:15504997
- View Article
- PubMed/NCBI
- Google Scholar
14. Kendall DM, Riddle MC, Rosenstock J, Zhuang DL, Kim DD, Fineman MS, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes mellitus treated with metformin and a sulfonylurea. Diabetes Care. 2005; 28: 1083–1091 pmid:15855571
- View Article
- PubMed/NCBI
- Google Scholar
15. Xu G, Kaneto H. GLP-1/exendin-4 facilitates β-cell neogenesis in rat and human pancreatic ducts. Diabetes Res Clin Pract. 2006; 73: 107–110 pmid:16406191
- View Article
- PubMed/NCBI
- Google Scholar
16. Drucker DJ, Nauck MA. The incretin system: glucagonlike peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. The Lancet. 2006; 368 (9548): 1696–1705
- View Article
- Google Scholar
17. Bydureon (exenatide extended-release for injectable suspension) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2014
18. Shaji J, Patole V. Protein and peptide drug delivery: oral approaches. Indian J Pharm Sci. 2008; 70 (3): 269–277 pmid:20046732
- View Article
- PubMed/NCBI
- Google Scholar
19. Rekha MA, Sharma CP. Oral delivery of therapeutic protein/peptide for diabetes–Future perspectives. Int J Pharm. 2013; 440: 48–62 pmid:22503954
- View Article
- PubMed/NCBI
- Google Scholar
20. Bouttefeux O, Beloqui A, Préat V. Delivery of peptides via the oral route: diabetes treatment by peptide-loaded nanoparticles. Curr Pharm Design. 2016; 22: 1161–1176
- View Article
- Google Scholar
21. Fonte P, Araujo F, Silva C, Pereira C, Reis S, Santos HA, et al. Polymer-based nanoparticles for oral insulin delivery: revisited approaches. Biotechnol Adv. 2015; 33: 1342–1354 pmid:25728065
- View Article
- PubMed/NCBI
- Google Scholar
22. Gupta V, Hwang BH, Doshi N, Banerjee A, Anselmo AC, Mitragotri S. Delivery of exenatide and insulin using mucoadhesive intestinal devices. Ann Biomed Eng. 2016; 44(6): 1993–2007 pmid:26864536
- View Article
- PubMed/NCBI
- Google Scholar
23. Sánchez-Navarro M, Garcia J, Giralt E, Teixidó M. Using peptides to increase transport across the intestinal barrier. Adv Drug Deliv Rev. 2016. http://dx.doi.org/10.1016/j.addr.2016.04.031
- View Article
- Google Scholar
24. Castro PM, Fonte P, Sousa F, Madureira AR, Sarmento B, Pintado ME. Oral films as breakthrough tools for oral delivery of proteins/peptides. J Control Release. 2015; 211: 63–73 pmid:25979328
- View Article
- PubMed/NCBI
- Google Scholar
25. Lopes M, Simoes S, Veiga F, Seica R, Ribeiro A. Why most oral insulin formulations do not reach clinical trials. Ther Deliv. 2015; 6: 1–15
- View Article
- Google Scholar
26. Wyszyńska A, Kobierecka P, Bardowski J, Jagusztyn-Krynicka EK. Lactic acid bacteria—20 years exploring their potential as live vectors for mucosal vaccination. Appl Microbiol Biotechnol. 2015; 99: 2967–2977 pmid:25750046
- View Article
- PubMed/NCBI
- Google Scholar
27. Cano-Garrido O, Seras-Franzoso J, Garcia-Fruitós E. Lactic acid bacteria: reviewing the potential of a promising delivery live vector for biomedical purposes. Microb Cell Fact. 2015; 14: 137 pmid:26377321
- View Article
- PubMed/NCBI
- Google Scholar
28. Wang W, Gao ZQ, Zhong YG, Pan L. Lactic acid bacteria as mucosal delivery vehicles: a realistic therapeutic option. Appl Microbiol Biotechnol. 2016; 100: 5691–5701 pmid:27154346
- View Article
- PubMed/NCBI
- Google Scholar
29. Gareau MG, Sherman PM, Walker WA. Probiotics and the gut microbiota in intestinal health and disease. Nat Rev Gastroenterol Hepatol. 2010; 7: 503–514 pmid:20664519
- View Article
- PubMed/NCBI
- Google Scholar
30. Ouwehand AC, Kirjavainen PV, Gronlund M-M, Isolauri E, Salminen S. Adhesion of probiotic micro-organisms to intestinal mucus. Int Dairy J. 1999; 9: 623–630
- View Article
- Google Scholar
31. Kaushal G, Trombetta L, Ochs RS, Shao J. Delivery of TEM beta-lactamase by gene-transformed Lactococcus lactis subsp. lactis through cervical cell monolayer. Int J Pharm. 2006; 313(1–2): 29–35 pmid:16488095
- View Article
- PubMed/NCBI
- Google Scholar
32. Braat H, Rottiers P, Hommes DW, Huyghebaert N, Remaut E, Remon JP, et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol. 2006; 4(6): 754–759 pmid:16716759
- View Article
- PubMed/NCBI
- Google Scholar
33. Ng DT, Sarkar CA. Nisin-inducible secretion of a biologically active single-chain insulin analog by Lactococcus lactis NZ9000. Biotechnol Bioeng. 2011; 108: 1987–1996 pmid:21391210
- View Article
- PubMed/NCBI
- Google Scholar
34. Ma Y, Liu J, Hou J, Dong Y, Lu Y, Jin L, et al. Oral administration of recombinant Lactococcus lactis expressing HSP65 and tandemly repeated P277 reduces the incidence of type I diabetes in non-obese diabetic mice. PLOS ONE. 2014; 9: e105701 pmid:25157497
- View Article
- PubMed/NCBI
- Google Scholar
35. Agarwal P, Khatri P, Billack B, Low W-K, Shao J. Oral delivery of glucagon like peptide-1 by a recombinant Lactococcus lactis. Pharm. Res. 2014; 31: 3404−3414 pmid:24928365
- View Article
- PubMed/NCBI
- Google Scholar
36. Robert S, Gysemans C, Takiishi T, Korf H, Spagnuolo I, Sebastiani G, et al. Oral delivery of glutamic acid decarboxylase (GAD)-65 and IL10 by Lactococcus lactis reverses diabetes in recent-onset NOD mice. Diabetes. 2014; 63: 2876–2887 pmid:24677716
- View Article
- PubMed/NCBI
- Google Scholar
37. Wei P, Yang Y, Li T, Ding Q, Sun H. An engineered Bifidobacterium longum secreting a bioactive penetratin-Glucagon-like peptide 1 fusion protein enhances Glucagon-like peptide 1 absorption in the intestine. J Microbiol Biotechn. 2015; pmid:25674803
- View Article
- PubMed/NCBI
- Google Scholar
38. Duan FF, Liu JH, March JC. Engineered commensal bacteria reprogram intestinal cells into glucose-responsive insulin-secreting cells for the treatment of diabetes. Diabetes. 2015; 64: 1794–1803 pmid:25626737
- View Article
- PubMed/NCBI
- Google Scholar
39. van de Guchte M, van der Vossen JMBM, Kok J, Venema G. Construction of a lactococcal expression vector: expression of hen egg white lysozyme in Lactococcus lactis subsp. lactis. Appl Environ Microbiol. 1989; 55: 224–228 pmid:2495760
- View Article
- PubMed/NCBI
- Google Scholar
40. Schägger H. Tricine-sds-page. Nat Protoc. 2006; 1: 16–22 pmid:17406207
- View Article
- PubMed/NCBI
- Google Scholar
41. Zhang B, Li AD, Zuo FL, Yu R, Zeng Z, Ma HQ, et al. Recombinant Lactococcus lactis NZ9000 secretes a bioactive kisspeptin that inhibits proliferation and migration of human colon carcinoma HT‑29 cells. Microb Cell Fact. 2016; 15: 102 pmid:27287327
- View Article
- PubMed/NCBI
- Google Scholar
42. Hohmeier HE, Mulder H, Chen GX, Henkel-Rieger R, Prentki M, Newgard CB. Isolation of INS-1–derived cell lines with robust ATP-sensitive K+ channel-dependent and-independent glucose-stimulated insulin secretion. Diabetes. 2000; 49: 424–430 pmid:10868964
- View Article
- PubMed/NCBI
- Google Scholar
43. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. Nat Protoc. 2008; 3: 1101–1108 pmid:18546601
- View Article
- PubMed/NCBI
- Google Scholar
44. Hubatsch I, Ragnarsson EGE, Artursson P. Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers. Nat Protoc. 2007; 2: 2111–2119 pmid:17853866
- View Article
- PubMed/NCBI
- Google Scholar
45. Habener JF, Stoffers DA. A newly discovered role of transcription factors involved in pancreas development and the pathogenesis of diabetes mellitus. Proc Assoc Am Physicians. 1998; 110: 12–21 pmid:9460079
- View Article
- PubMed/NCBI
- Google Scholar
46. Stoffers DA, Kieffer TJ, Hussain MA, Drucker DJ, Bonner-Weir S, Habener JF, et al. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes. 2000; 49: 741–748 pmid:10905482
- View Article
- PubMed/NCBI
- Google Scholar
47. Wang X, Zhou J, Doyle ME, Egan JM. Glucagon-like peptide-1 causes pancreatic duodenal homeobox-1 protein translocation from the cytoplasm to the nucleus of pancreatic beta-cells by a cyclic adenosine monophosphate/protein kinase A-dependent mechanism. Endocrinology. 2001; 142: 1820–1827 pmid:11316746
- View Article
- PubMed/NCBI
- Google Scholar
48. Thum A, Hupe-Sodmann K, Goke R, Voigt K, Goke B, McGregor GP. Endoproteolysis by isolated membrane peptidases reveal metabolic stability of glucagon-like peptide-1 analogs, exendins-3 and -4. Exp Clin Endocrinol Diabetes. 2002; 110: 113–118 pmid:12012270
- View Article
- PubMed/NCBI
- Google Scholar
49. Belmokhtar CA, Hillion J, Ségal-Bendirdjian E. Staurosporine induces apoptosis through both caspase-dependent and caspase-independent mechanisms. Oncogene. 2001; 20(26): 3354–3362 pmid:11423986
- View Article
- PubMed/NCBI
- Google Scholar
50. Thuret G, Chiquet C, Herrag S, Dumollard JM, Boudard D, Bednarz J, et al. Mechanisms of staurosporine induced apoptosis in a human corneal endothelial cell line. Br J Ophthalmol. 2003; 87(3): 346–352 pmid:12598452
- View Article
- PubMed/NCBI
- Google Scholar
51. Shao J, Kaushal G. Normal flora: living vehicles for non-invasive protein drug delivery. Int J of Pharm. 2004; 286: 117–124
- View Article
- Google Scholar
52. Le Loir Y, Nouaille S, Commissaire J, Brétigny L, Gruss A, Langella P. Signal peptide and propeptide optimization for heterologous protein secretion in Lactococcus lactis. Appl Environ Microbiol. 2001; 67(9): 4119–4127 pmid:11526014
- View Article
- PubMed/NCBI
- Google Scholar
53. Schotte L, Steidler L, Vandekerckhove J, Remaut E. Secretion of biologically active murine interleukin-10 by Lactococcus lactis. Enzyme Microb Technol. 2000; 27(10): 761–765 pmid:11118583
- View Article
- PubMed/NCBI
- Google Scholar
54. Khokhlova EV, Efimov AB, Kafarskaia LI, Shkoporov AN. Heterologous expression of secreted biologically active human interleukin-10 in Bifidobacterium breve. Arch Microbiol. 2010; 192: 769–774 pmid:20631991
- View Article
- PubMed/NCBI
- Google Scholar
55. Wells JM, Mercenier A. Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat Rev Microbiol. 2008; 6(5): 349–362 pmid:18345021
- View Article
- PubMed/NCBI
- Google Scholar
56. Hartstra AV, Bouter KEC, Bäckhed F, Nieuwdorp M. Insights into the role of the microbiome in obesity and type 2 diabetes. Diabetes Care. 2015; 38: 159–165 pmid:25538312
- View Article
- PubMed/NCBI
- Google Scholar
57. Charman WN, Porter CJ, Mithani S, Dressman JB. Physiochemical and physiological mechanisms for the effects of food on drug absorption: The role of lipids and pH. J Pharm Sci. 1997; 86(3): 269–282 pmid:9050793
- View Article
- PubMed/NCBI
- Google Scholar
58. Chepurny OG, Hussain MA, Holz GG. Exendin-4 as a stimulator of rat insulin I gene promoter activity via bZIP/CRE interactions sensitive to serine/threonine protein kinase inhibitor Ro 31–8220. Endocrinology. 2002; 143: 2303–2313 pmid:12021195
- View Article
- PubMed/NCBI
- Google Scholar
59. Hirayama K, Rafter J. The role of lactic acid bacteria in colon cancer prevention: mechanistic considerations. Antonie van Leeuwenhoek. 1999; 76: 391–394 pmid:10532395
- View Article
- PubMed/NCBI
- Google Scholar
60. Nami Y, Abdullah N, Haghshenas B, Radiah D, Rosli R, Khosroushahi AY. Probiotic potential and biotherapeutic effects of newly isolated vaginal Lactobacillus acidophilus 36YL strain on cancer cells. Anaerobe. 2014; 28: 29–36 pmid:24818631
- View Article
- PubMed/NCBI
- Google Scholar
61. Pinto M, Robine-Leon S, Appay M-D, Kedinger M, Triadou N, Dussaulx E, et al. Enterocyte-like differentiation and polarization of the human colon carcinoma cell line Caco-2 in culture. Biol Cell.1983; 47: 323–330
- View Article
- Google Scholar
62. Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, Tuohy KM, et al. Selective increases of bifidobacteria in gut microflora improve high-fat diet- induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia. 2007; 50: 2374–2383 pmid:17823788
- View Article
- PubMed/NCBI
- Google Scholar
63. Baboota RK, Bishnoi M, Ambalam P, Kondepudi KK, Sarma SM, Boparai RK, et al. Functional food ingredients for the management of obesity and associated co-morbidities–A review. J Funct Foods. 2013; 5: 997–1012
- View Article
- Google Scholar
64. Miyoshi M, Ogawa A, Higurashi S, Kadooka Y. Antiobesity effect of Lactobacillus gasseri SBT2055 accompanied by inhibition of pro-inflammatory gene expression in the visceral adipose tissue in diet-induced obese mice. Eur J Nutr. 2014; 53: 599–606 pmid:23917447
- View Article
- PubMed/NCBI
- Google Scholar
65. Zeng Z, Luo JY, Zuo FL, Zhang Y, Ma HQ, Chen SW. Screening for potential novel probiotic Lactobacillus strains based on high dipeptidyl peptidase IV and α-glucosidase inhibitory activity. J Funct Foods. 2016; 20: 486–495
- View Article
- Google Scholar

[ref1] 1. Drucker DJ. Glucagon-like peptides. Diabetes. 1998; 47: 159–169 pmid:9519708
View Article
PubMed/NCBI
Google Scholar

[2] View Article

[3] PubMed/NCBI

[4] Google Scholar

[ref2] 2. Nauck MA, Wollschlager D, Werner J, Holst JJ, Ørskov C, Creutzfeldt W, et al. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7–36 amide]) in patients with NIDDM. Diabetologia. 1996; 39: 1546–1553 pmid:8960841
View Article
PubMed/NCBI
Google Scholar

[6] View Article

[7] PubMed/NCBI

[8] Google Scholar

[ref3] 3. Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA. Gastric emptying, glucose responses and insulin secretion after a liquid test meal: Effects of exogenous glucagon-like peptide-1 (GLP-1)-(7–36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab. 1996; 81: 327–332 pmid:8550773
View Article
PubMed/NCBI
Google Scholar

[10] View Article

[11] PubMed/NCBI

[12] Google Scholar

[ref4] 4. Wang Q, Li L, Xu E, Wong V, Rhodes C, Brubaker PL. Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells. Diabetologia. 2004; 47: 478–487 pmid:14762654
View Article
PubMed/NCBI
Google Scholar

[14] View Article

[15] PubMed/NCBI

[16] Google Scholar

[ref5] 5. Verspohl EJ. Novel therapeutics for type 2 diabetes: Incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Therapeut. 2009; 124: 113–138
View Article
Google Scholar

[18] View Article

[19] Google Scholar

[ref6] 6. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet. 2002; 359: 824–830 pmid:11897280
View Article
PubMed/NCBI
Google Scholar

[21] View Article

[22] PubMed/NCBI

[23] Google Scholar

[ref7] 7. Sarkar G, Alattar M, Brown RJ, Quon MJ, Harlan DM, Rother KI. Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes. Diabetes Care. 2014; 37: 666–670 pmid:24194508
View Article
PubMed/NCBI
Google Scholar

[25] View Article

[26] PubMed/NCBI

[27] Google Scholar

[ref8] 8. Holst JJ, Deacon CF. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes. 1998; 47: 1663–1670 pmid:9792533
View Article
PubMed/NCBI
Google Scholar

[29] View Article

[30] PubMed/NCBI

[31] Google Scholar

[ref9] 9. Neumiller JJ. Incretin-based therapies. Med Clin North Am. 2015; 99(1): 107–129 pmid:25456646
View Article
PubMed/NCBI
Google Scholar

[33] View Article

[34] PubMed/NCBI

[35] Google Scholar

[ref10] 10. Mest HJ, Mentlein R. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes. Diabetologia. 2005; 48(4): 616–620 pmid:15770466
View Article
PubMed/NCBI
Google Scholar

[37] View Article

[38] PubMed/NCBI

[39] Google Scholar

[ref11] 11. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem. 1992; 267: 7402–7405 pmid:1313797
View Article
PubMed/NCBI
Google Scholar

[41] View Article

[42] PubMed/NCBI

[43] Google Scholar

[ref12] 12. Edwards CM, Stanley SA, Davis R, Brynes AE, Frost GS, Seal LJ, et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab. 2001; 281: E155–E161 pmid:11404233
View Article
PubMed/NCBI
Google Scholar

[45] View Article

[46] PubMed/NCBI

[47] Google Scholar

[ref13] 13. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea treated patients with type 2 diabetes. Diabetes Care. 2004; 27: 2628–2635 pmid:15504997
View Article
PubMed/NCBI
Google Scholar

[49] View Article

[50] PubMed/NCBI

[51] Google Scholar

[ref14] 14. Kendall DM, Riddle MC, Rosenstock J, Zhuang DL, Kim DD, Fineman MS, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes mellitus treated with metformin and a sulfonylurea. Diabetes Care. 2005; 28: 1083–1091 pmid:15855571
View Article
PubMed/NCBI
Google Scholar

[53] View Article

[54] PubMed/NCBI

[55] Google Scholar

[ref15] 15. Xu G, Kaneto H. GLP-1/exendin-4 facilitates β-cell neogenesis in rat and human pancreatic ducts. Diabetes Res Clin Pract. 2006; 73: 107–110 pmid:16406191
View Article
PubMed/NCBI
Google Scholar

[57] View Article

[58] PubMed/NCBI

[59] Google Scholar

[ref16] 16. Drucker DJ, Nauck MA. The incretin system: glucagonlike peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. The Lancet. 2006; 368 (9548): 1696–1705
View Article
Google Scholar

[61] View Article

[62] Google Scholar

[ref17] 17. Bydureon (exenatide extended-release for injectable suspension) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2014

[ref18] 18. Shaji J, Patole V. Protein and peptide drug delivery: oral approaches. Indian J Pharm Sci. 2008; 70 (3): 269–277 pmid:20046732
View Article
PubMed/NCBI
Google Scholar

[65] View Article

[66] PubMed/NCBI

[67] Google Scholar

[ref19] 19. Rekha MA, Sharma CP. Oral delivery of therapeutic protein/peptide for diabetes–Future perspectives. Int J Pharm. 2013; 440: 48–62 pmid:22503954
View Article
PubMed/NCBI
Google Scholar

[69] View Article

[70] PubMed/NCBI

[71] Google Scholar

[ref20] 20. Bouttefeux O, Beloqui A, Préat V. Delivery of peptides via the oral route: diabetes treatment by peptide-loaded nanoparticles. Curr Pharm Design. 2016; 22: 1161–1176
View Article
Google Scholar

[73] View Article

[74] Google Scholar

[ref21] 21. Fonte P, Araujo F, Silva C, Pereira C, Reis S, Santos HA, et al. Polymer-based nanoparticles for oral insulin delivery: revisited approaches. Biotechnol Adv. 2015; 33: 1342–1354 pmid:25728065
View Article
PubMed/NCBI
Google Scholar

[76] View Article

[77] PubMed/NCBI

[78] Google Scholar

[ref22] 22. Gupta V, Hwang BH, Doshi N, Banerjee A, Anselmo AC, Mitragotri S. Delivery of exenatide and insulin using mucoadhesive intestinal devices. Ann Biomed Eng. 2016; 44(6): 1993–2007 pmid:26864536
View Article
PubMed/NCBI
Google Scholar

[80] View Article

[81] PubMed/NCBI

[82] Google Scholar

[ref23] 23. Sánchez-Navarro M, Garcia J, Giralt E, Teixidó M. Using peptides to increase transport across the intestinal barrier. Adv Drug Deliv Rev. 2016. http://dx.doi.org/10.1016/j.addr.2016.04.031
View Article
Google Scholar

[84] View Article

[85] Google Scholar

[ref24] 24. Castro PM, Fonte P, Sousa F, Madureira AR, Sarmento B, Pintado ME. Oral films as breakthrough tools for oral delivery of proteins/peptides. J Control Release. 2015; 211: 63–73 pmid:25979328
View Article
PubMed/NCBI
Google Scholar

[87] View Article

[88] PubMed/NCBI

[89] Google Scholar

[ref25] 25. Lopes M, Simoes S, Veiga F, Seica R, Ribeiro A. Why most oral insulin formulations do not reach clinical trials. Ther Deliv. 2015; 6: 1–15
View Article
Google Scholar

[91] View Article

[92] Google Scholar

[ref26] 26. Wyszyńska A, Kobierecka P, Bardowski J, Jagusztyn-Krynicka EK. Lactic acid bacteria—20 years exploring their potential as live vectors for mucosal vaccination. Appl Microbiol Biotechnol. 2015; 99: 2967–2977 pmid:25750046
View Article
PubMed/NCBI
Google Scholar

[94] View Article

[95] PubMed/NCBI

[96] Google Scholar

[ref27] 27. Cano-Garrido O, Seras-Franzoso J, Garcia-Fruitós E. Lactic acid bacteria: reviewing the potential of a promising delivery live vector for biomedical purposes. Microb Cell Fact. 2015; 14: 137 pmid:26377321
View Article
PubMed/NCBI
Google Scholar

[98] View Article

[99] PubMed/NCBI

[100] Google Scholar

[ref28] 28. Wang W, Gao ZQ, Zhong YG, Pan L. Lactic acid bacteria as mucosal delivery vehicles: a realistic therapeutic option. Appl Microbiol Biotechnol. 2016; 100: 5691–5701 pmid:27154346
View Article
PubMed/NCBI
Google Scholar

[102] View Article

[103] PubMed/NCBI

[104] Google Scholar

[ref29] 29. Gareau MG, Sherman PM, Walker WA. Probiotics and the gut microbiota in intestinal health and disease. Nat Rev Gastroenterol Hepatol. 2010; 7: 503–514 pmid:20664519
View Article
PubMed/NCBI
Google Scholar

[106] View Article

[107] PubMed/NCBI

[108] Google Scholar

[ref30] 30. Ouwehand AC, Kirjavainen PV, Gronlund M-M, Isolauri E, Salminen S. Adhesion of probiotic micro-organisms to intestinal mucus. Int Dairy J. 1999; 9: 623–630
View Article
Google Scholar

[110] View Article

[111] Google Scholar

[ref31] 31. Kaushal G, Trombetta L, Ochs RS, Shao J. Delivery of TEM beta-lactamase by gene-transformed Lactococcus lactis subsp. lactis through cervical cell monolayer. Int J Pharm. 2006; 313(1–2): 29–35 pmid:16488095
View Article
PubMed/NCBI
Google Scholar

[113] View Article

[114] PubMed/NCBI

[115] Google Scholar

[ref32] 32. Braat H, Rottiers P, Hommes DW, Huyghebaert N, Remaut E, Remon JP, et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol. 2006; 4(6): 754–759 pmid:16716759
View Article
PubMed/NCBI
Google Scholar

[117] View Article

[118] PubMed/NCBI

[119] Google Scholar

[ref33] 33. Ng DT, Sarkar CA. Nisin-inducible secretion of a biologically active single-chain insulin analog by Lactococcus lactis NZ9000. Biotechnol Bioeng. 2011; 108: 1987–1996 pmid:21391210
View Article
PubMed/NCBI
Google Scholar

[121] View Article

[122] PubMed/NCBI

[123] Google Scholar

[ref34] 34. Ma Y, Liu J, Hou J, Dong Y, Lu Y, Jin L, et al. Oral administration of recombinant Lactococcus lactis expressing HSP65 and tandemly repeated P277 reduces the incidence of type I diabetes in non-obese diabetic mice. PLOS ONE. 2014; 9: e105701 pmid:25157497
View Article
PubMed/NCBI
Google Scholar

[125] View Article

[126] PubMed/NCBI

[127] Google Scholar

[ref35] 35. Agarwal P, Khatri P, Billack B, Low W-K, Shao J. Oral delivery of glucagon like peptide-1 by a recombinant Lactococcus lactis. Pharm. Res. 2014; 31: 3404−3414 pmid:24928365
View Article
PubMed/NCBI
Google Scholar

[129] View Article

[130] PubMed/NCBI

[131] Google Scholar

[ref36] 36. Robert S, Gysemans C, Takiishi T, Korf H, Spagnuolo I, Sebastiani G, et al. Oral delivery of glutamic acid decarboxylase (GAD)-65 and IL10 by Lactococcus lactis reverses diabetes in recent-onset NOD mice. Diabetes. 2014; 63: 2876–2887 pmid:24677716
View Article
PubMed/NCBI
Google Scholar

[133] View Article

[134] PubMed/NCBI

[135] Google Scholar

[ref37] 37. Wei P, Yang Y, Li T, Ding Q, Sun H. An engineered Bifidobacterium longum secreting a bioactive penetratin-Glucagon-like peptide 1 fusion protein enhances Glucagon-like peptide 1 absorption in the intestine. J Microbiol Biotechn. 2015; pmid:25674803
View Article
PubMed/NCBI
Google Scholar

[137] View Article

[138] PubMed/NCBI

[139] Google Scholar

[ref38] 38. Duan FF, Liu JH, March JC. Engineered commensal bacteria reprogram intestinal cells into glucose-responsive insulin-secreting cells for the treatment of diabetes. Diabetes. 2015; 64: 1794–1803 pmid:25626737
View Article
PubMed/NCBI
Google Scholar

[141] View Article

[142] PubMed/NCBI

[143] Google Scholar

[ref39] 39. van de Guchte M, van der Vossen JMBM, Kok J, Venema G. Construction of a lactococcal expression vector: expression of hen egg white lysozyme in Lactococcus lactis subsp. lactis. Appl Environ Microbiol. 1989; 55: 224–228 pmid:2495760
View Article
PubMed/NCBI
Google Scholar

[145] View Article

[146] PubMed/NCBI

[147] Google Scholar

[ref40] 40. Schägger H. Tricine-sds-page. Nat Protoc. 2006; 1: 16–22 pmid:17406207
View Article
PubMed/NCBI
Google Scholar

[149] View Article

[150] PubMed/NCBI

[151] Google Scholar

[ref41] 41. Zhang B, Li AD, Zuo FL, Yu R, Zeng Z, Ma HQ, et al. Recombinant Lactococcus lactis NZ9000 secretes a bioactive kisspeptin that inhibits proliferation and migration of human colon carcinoma HT‑29 cells. Microb Cell Fact. 2016; 15: 102 pmid:27287327
View Article
PubMed/NCBI
Google Scholar

[153] View Article

[154] PubMed/NCBI

[155] Google Scholar

[ref42] 42. Hohmeier HE, Mulder H, Chen GX, Henkel-Rieger R, Prentki M, Newgard CB. Isolation of INS-1–derived cell lines with robust ATP-sensitive K+ channel-dependent and-independent glucose-stimulated insulin secretion. Diabetes. 2000; 49: 424–430 pmid:10868964
View Article
PubMed/NCBI
Google Scholar

[157] View Article

[158] PubMed/NCBI

[159] Google Scholar

[ref43] 43. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. Nat Protoc. 2008; 3: 1101–1108 pmid:18546601
View Article
PubMed/NCBI
Google Scholar

[161] View Article

[162] PubMed/NCBI

[163] Google Scholar

[ref44] 44. Hubatsch I, Ragnarsson EGE, Artursson P. Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers. Nat Protoc. 2007; 2: 2111–2119 pmid:17853866
View Article
PubMed/NCBI
Google Scholar

[165] View Article

[166] PubMed/NCBI

[167] Google Scholar

[ref45] 45. Habener JF, Stoffers DA. A newly discovered role of transcription factors involved in pancreas development and the pathogenesis of diabetes mellitus. Proc Assoc Am Physicians. 1998; 110: 12–21 pmid:9460079
View Article
PubMed/NCBI
Google Scholar

[169] View Article

[170] PubMed/NCBI

[171] Google Scholar

[ref46] 46. Stoffers DA, Kieffer TJ, Hussain MA, Drucker DJ, Bonner-Weir S, Habener JF, et al. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes. 2000; 49: 741–748 pmid:10905482
View Article
PubMed/NCBI
Google Scholar

[173] View Article

[174] PubMed/NCBI

[175] Google Scholar

[ref47] 47. Wang X, Zhou J, Doyle ME, Egan JM. Glucagon-like peptide-1 causes pancreatic duodenal homeobox-1 protein translocation from the cytoplasm to the nucleus of pancreatic beta-cells by a cyclic adenosine monophosphate/protein kinase A-dependent mechanism. Endocrinology. 2001; 142: 1820–1827 pmid:11316746
View Article
PubMed/NCBI
Google Scholar

[177] View Article

[178] PubMed/NCBI

[179] Google Scholar

[ref48] 48. Thum A, Hupe-Sodmann K, Goke R, Voigt K, Goke B, McGregor GP. Endoproteolysis by isolated membrane peptidases reveal metabolic stability of glucagon-like peptide-1 analogs, exendins-3 and -4. Exp Clin Endocrinol Diabetes. 2002; 110: 113–118 pmid:12012270
View Article
PubMed/NCBI
Google Scholar

[181] View Article

[182] PubMed/NCBI

[183] Google Scholar

[ref49] 49. Belmokhtar CA, Hillion J, Ségal-Bendirdjian E. Staurosporine induces apoptosis through both caspase-dependent and caspase-independent mechanisms. Oncogene. 2001; 20(26): 3354–3362 pmid:11423986
View Article
PubMed/NCBI
Google Scholar

[185] View Article

[186] PubMed/NCBI

[187] Google Scholar

[ref50] 50. Thuret G, Chiquet C, Herrag S, Dumollard JM, Boudard D, Bednarz J, et al. Mechanisms of staurosporine induced apoptosis in a human corneal endothelial cell line. Br J Ophthalmol. 2003; 87(3): 346–352 pmid:12598452
View Article
PubMed/NCBI
Google Scholar

[189] View Article

[190] PubMed/NCBI

[191] Google Scholar

[ref51] 51. Shao J, Kaushal G. Normal flora: living vehicles for non-invasive protein drug delivery. Int J of Pharm. 2004; 286: 117–124
View Article
Google Scholar

[193] View Article

[194] Google Scholar

[ref52] 52. Le Loir Y, Nouaille S, Commissaire J, Brétigny L, Gruss A, Langella P. Signal peptide and propeptide optimization for heterologous protein secretion in Lactococcus lactis. Appl Environ Microbiol. 2001; 67(9): 4119–4127 pmid:11526014
View Article
PubMed/NCBI
Google Scholar

[196] View Article

[197] PubMed/NCBI

[198] Google Scholar

[ref53] 53. Schotte L, Steidler L, Vandekerckhove J, Remaut E. Secretion of biologically active murine interleukin-10 by Lactococcus lactis. Enzyme Microb Technol. 2000; 27(10): 761–765 pmid:11118583
View Article
PubMed/NCBI
Google Scholar

[200] View Article

[201] PubMed/NCBI

[202] Google Scholar

[ref54] 54. Khokhlova EV, Efimov AB, Kafarskaia LI, Shkoporov AN. Heterologous expression of secreted biologically active human interleukin-10 in Bifidobacterium breve. Arch Microbiol. 2010; 192: 769–774 pmid:20631991
View Article
PubMed/NCBI
Google Scholar

[204] View Article

[205] PubMed/NCBI

[206] Google Scholar

[ref55] 55. Wells JM, Mercenier A. Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat Rev Microbiol. 2008; 6(5): 349–362 pmid:18345021
View Article
PubMed/NCBI
Google Scholar

[208] View Article

[209] PubMed/NCBI

[210] Google Scholar

[ref56] 56. Hartstra AV, Bouter KEC, Bäckhed F, Nieuwdorp M. Insights into the role of the microbiome in obesity and type 2 diabetes. Diabetes Care. 2015; 38: 159–165 pmid:25538312
View Article
PubMed/NCBI
Google Scholar

[212] View Article

[213] PubMed/NCBI

[214] Google Scholar

[ref57] 57. Charman WN, Porter CJ, Mithani S, Dressman JB. Physiochemical and physiological mechanisms for the effects of food on drug absorption: The role of lipids and pH. J Pharm Sci. 1997; 86(3): 269–282 pmid:9050793
View Article
PubMed/NCBI
Google Scholar

[216] View Article

[217] PubMed/NCBI

[218] Google Scholar

[ref58] 58. Chepurny OG, Hussain MA, Holz GG. Exendin-4 as a stimulator of rat insulin I gene promoter activity via bZIP/CRE interactions sensitive to serine/threonine protein kinase inhibitor Ro 31–8220. Endocrinology. 2002; 143: 2303–2313 pmid:12021195
View Article
PubMed/NCBI
Google Scholar

[220] View Article

[221] PubMed/NCBI

[222] Google Scholar

[ref59] 59. Hirayama K, Rafter J. The role of lactic acid bacteria in colon cancer prevention: mechanistic considerations. Antonie van Leeuwenhoek. 1999; 76: 391–394 pmid:10532395
View Article
PubMed/NCBI
Google Scholar

[224] View Article

[225] PubMed/NCBI

[226] Google Scholar

[ref60] 60. Nami Y, Abdullah N, Haghshenas B, Radiah D, Rosli R, Khosroushahi AY. Probiotic potential and biotherapeutic effects of newly isolated vaginal Lactobacillus acidophilus 36YL strain on cancer cells. Anaerobe. 2014; 28: 29–36 pmid:24818631
View Article
PubMed/NCBI
Google Scholar

[228] View Article

[229] PubMed/NCBI

[230] Google Scholar

[ref61] 61. Pinto M, Robine-Leon S, Appay M-D, Kedinger M, Triadou N, Dussaulx E, et al. Enterocyte-like differentiation and polarization of the human colon carcinoma cell line Caco-2 in culture. Biol Cell.1983; 47: 323–330
View Article
Google Scholar

[232] View Article

[233] Google Scholar

[ref62] 62. Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, Tuohy KM, et al. Selective increases of bifidobacteria in gut microflora improve high-fat diet- induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia. 2007; 50: 2374–2383 pmid:17823788
View Article
PubMed/NCBI
Google Scholar

[235] View Article

[236] PubMed/NCBI

[237] Google Scholar

[ref63] 63. Baboota RK, Bishnoi M, Ambalam P, Kondepudi KK, Sarma SM, Boparai RK, et al. Functional food ingredients for the management of obesity and associated co-morbidities–A review. J Funct Foods. 2013; 5: 997–1012
View Article
Google Scholar

[239] View Article

[240] Google Scholar

[ref64] 64. Miyoshi M, Ogawa A, Higurashi S, Kadooka Y. Antiobesity effect of Lactobacillus gasseri SBT2055 accompanied by inhibition of pro-inflammatory gene expression in the visceral adipose tissue in diet-induced obese mice. Eur J Nutr. 2014; 53: 599–606 pmid:23917447
View Article
PubMed/NCBI
Google Scholar

[242] View Article

[243] PubMed/NCBI

[244] Google Scholar

[ref65] 65. Zeng Z, Luo JY, Zuo FL, Zhang Y, Ma HQ, Chen SW. Screening for potential novel probiotic Lactobacillus strains based on high dipeptidyl peptidase IV and α-glucosidase inhibitory activity. J Funct Foods. 2016; 20: 486–495
View Article
Google Scholar

[246] View Article

[247] Google Scholar

Figures

Abstract

Introduction

Materials and Methods

Materials

Bacterial strains, plasmids, and growth conditions

DNA manipulation and transformation

Recombinant exendin-4 extraction and western blot analysis

Indirect ELISA quantification of secreted exendin-4

Cell culture of rat insulinoma cell line INS-1

Insulin secretion assay

Quantitative reverse transcription PCR (qRT-PCR) analysis of expression of PDX-1 and Insulin

Cell-proliferation and apoptosis assay

Transport of exendin-4 through Caco-2 monolayer

Statistical analysis

Results

Expression of recombinant exendin-4 in L. paracasei L14

Recombinant exendin-4's insulinotropic effect in INS-1 cells

Recombinant exendin-4 increases mRNA expression of PDX-1 and the insulin gene

Recombinant exendin-4 enhances INS-1 cell proliferation and decreases staurosporine-induced cell apoptosis

Delivery of exendin-4 by L14/pMG76e-exendin-4 through Caco-2 cell monolayer

Discussion

Conclusions

Supporting Information

S1 Fig. The effect of glucose concentration on GLP-1-stimulated insulin secretion from INS-1 cells.

Author Contributions

References